Übersicht – Diagnostik von Knochentumoren

Die WHO klassifiziert Knochen- und Weichteiltumoren nach ihrer Liniendifferenzierung und Dignität, wobei 2013 erstmalig neben benignen und malignen Knochentumoren auch intermediäre Formen aufgeführt wurden ([Tab. 1]) [1]. Letztere gliedern sich in lokal aggressive (z. B. Osteoblastom) und selten metastasierende Tumortypen (z. B. Chondroblastom).

• Literatur

• 1 Fletcher CDM, Bridge JA, Hogendoorn PCW et al. WHO Classification of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2013
• 2 Lodwick GS, Wilson AJ, Farrell C et al. Determining growth rates of focal lesions of bone from radiographs. Radiology 1980; 134: 577-583
• 3 Amary MF, Bacsi K, Maggiani F et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. The Journal of pathology 2011; 224: 334-343
• 4 de Andrea CE, Reijnders CM, Kroon HM et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene 2012; 31: 1095-1104
• 5 Wan Y, Zhao W, Jiang Y et al. beta-catenin is a valuable marker for differential diagnosis of osteoblastoma and osteosarcoma. Hum Pathol 2014; 45: 1459-1465
• 6 Kurt AM, Unni KK, McLeod RA et al. Low-grade intraosseous osteosarcoma. Cancer 1990; 65: 1418-1428
• 7 Oliveira AM, Hsi BL, Weremowicz S et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res 2004; 64: 1920-1923
• 8 Agaram NP, LeLoarer FV, Zhang L et al. USP6 gene rearrangements occur preferentially in giant cell reparative granulomas of the hands and feet but not in gnathic location. Hum Pathol 2014; 45: 1147-1152
• 9 Behjati S, Tarpey PS, Presneau N et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature genetics 2013; 45: 1479-1482